Key Highlights: Implications: Imfinzi storms endometrial cancer protocols, giving oncologists a potent immunotherapy combo that leapfrogs chemo-only standards. AstraZeneca doubles do...
Key Highlights: Implications: IIL grabs first-mover advantage in niche viral vaccine space, dominating government tenders and regional immunization drives. Homegrown breakthrough smashes i...
Key Highlights: Implications: This partnership accelerates peptide therapy access in high-growth markets, challenging incumbents like Sun Pharma in India’s $500M+ peptide segment whi...
Key Highlights: Implications: Durvalumab storms earlier gastric cancer treatment, snatching share from chemo-only protocols as oncologists embrace immunotherapy combo superiority.&nb...
Key Highlights: Implications: Sun ignites generics price war against Novo/Eli Lilly premium brands, slashing obesity therapy costs and exploding Tier-2/3 access. Dual T2D/weight...
Key Highlights: Implications: India’s pet care market reaches $3.6B in 2024, growing 20% CAGR to $24.8B by 2032; veterinary healthcare hits $1.76B by 2026 (8.64% CAGR)—partnership ta...
Key Highlights: Implications: Tishtha detonates pricing bombs on Roche’s Tecentriq and MSD’s Opdivo, handing cash-strapped hospitals a lifeline while exploding p...
Key Highlights: Implications: Quality failures erode trust in high-volume generics, handing innovator brands a compliance advantage as hospitals pivot to verified suppliers. Tie...
Key Highlights: Implications: Jubilant catapults into top-tier CRO/CDMO contender, snatching complex molecule work from Lonza/Capricor as India chemistry talent goes global. Noid...
Key Highlights: Implications: The appointment underlines ChemWerth’s intent to treat India not just as a sourcing base but as a strategic growth market for its re...